BMB Reports Papers in Press available online.

Search Papers In Press
This galley proof is being listed electronically before publishing the final manuscript (It's not final version).

 
Drug resistance of bladder cancer cells through activation of ABCG2 by FOXM1
Yun-Gil Roh1, Mi-Hye Mun1, Mi-So Jeong1, Won-Tae Kim1, Se-Ra Lee2, Jin-Woong Chung1, Seung Il Kim3,4, Tae Nam Kim5, Jong Kil Nam6, Sun-Hee Leem1,*
1Department of Biological Science, College of Natural Science, Dong-A University,
2Division of Drug Development & Optimization, Osong Medical Innovation Foundation (KBio),
3Drug & Disease Target Team, Korea Basic Science Institute,
4Center for Convergent Research of Emerging Virus Infection, Korea Research Institute of Chemical Technology,
5Department of Urology, Medical Research Institute, Pusan National University Hospital,
6Department of Urology, Research Institute for Convergence of Biochemical Science and Technology, Pusan National University Yangsan Hospital
Abstract
Recurrence is a serious problem in patients with bladder cancer. The hypothesis for recurrence was that the proliferation of drug-resistant cells was reported, and this study focused on drug resistance due to drug efflux. Previous studies have identified FOXM1 as the key gene for recurrence. We found that FOXM1 inhibition decreased drug efflux activity and increased sensitivity to Doxorubicin. Therefore, we examined whether the expression of ABC transporter gene related to drug efflux is regulated by FOXM1. As a result, ABCG2, one of the genes involved in drug efflux, has been identified as a new target for FOXM1. We also demonstrated direct transcriptional regulation of ABCG2 by FOXM1 using ChIP assay. Consequently, in the presence of the drug, FOXM1 is proposed to directly activate ABCG2 to increase the drug efflux activation and drug resistance, thereby involving chemoresistance of bladder cancer cells. Therefore, we suggest that FOXM1 and ABCG2 may be useful targets and important parameters in the treatment of bladder cancer.
Abstract, Accepted Manuscript(in press) [Submitted on November 24, 2017, Accepted on February 2, 2018]
  Copyright © KSBMB. All rights reserved. / Powered by INFOrang.co., Ltd